Hyperdoma™: A High-Throughput Hybridoma Generation Platform

Background Featured Platform Featured Systems Advantages

Background

In the domain of monoclonal antibody production, Hyperdoma™ shines as a beacon of innovation and efficiency. At Creative Biolabs, our cutting-edge platform harnesses advanced biotechnology to expedite and refine hybridoma generation, thereby revolutionizing the workflow for researchers globally. The core of Hyperdoma™ is its electrofusion system, integrated with high-throughput screening systems, which guarantees unparalleled accuracy and productivity.

Electrofusion System in Hyperdoma™ Platform

Electrofusion is a process that merges spleen cells with myeloma cells through the application of electric shocks. This rapidly advancing technique has found widespread application in life science research, biotechnology, and medicine.

Precision Fusion Technology

Our electrofusion system employs precision-controlled electrical pulses to fuse B-cells with myeloma cells, creating hybridomas with remarkable consistency and efficiency.

Customizable Parameters

Our system offers customizable electrofusion parameters, allowing researchers to tailor the process to their specific cell types and fusion requirements, ensuring optimal hybridoma formation tailored to your unique needs.

Automated and Reproducible

Automating the electrofusion process reduces human error and variability, ensuring highly reproducible results across experiments. This consistency is crucial for scalable and reliable hybridoma production.

High Fusion Efficiency

By employing this method, a high fusion success rate can be attained, generating up to 10³ to 10⁴ positive clones per fusion. The exponentially growing pool of positive clones substantially boosts the chances of isolating functional clones.

High-Throughput Hybridoma Screening Systems

Hybridoma screening, which involves identifying positive hybridoma clones that secrete functional antibodies, is a pivotal step in antibody discovery. Creative Biolabs has embraced several cutting-edge high-throughput screening methodologies that seamlessly integrate with the electrofusion system, enabling the efficient and fully automated exploitation of the extensive positive clone pool.

CLL-specific antibodies screening. Fig.1 Generation and binding characterization of CLL-specific antibodies.¹

ClonePix 2 System

ClonePix 2 stands as a highly automated system that precisely selects and deposits positive hybridoma colonies for screening. By utilizing a gel-like matrix to stabilize colony positioning and leveraging robotic design, this system significantly minimizes the risk of colony disruption and physical harm, while boosting workflow efficiency through reduced plate handling steps.

Fluorometric Microvolume Assay Technology (FMAT)

FMAT revolutionizes hybridoma screening by enabling high-throughput, sensitive, and accurate detection of antigen-specific antibodies in a microvolume format. This technology leverages fluorescent labeling to rapidly identify functional clones, significantly enhancing the efficiency and reliability of the screening process.

Celigo Image Cytometer

Creative Biolabs has incorporated and optimized high-throughput cell-based assays using the Celigo Image Cytometer, enabling direct visualization and analysis of live cells that have been bound with antibodies. By utilizing the Celigo Image Cytometer, we've streamlined the process of identifying and selecting positive clones, drastically cutting down the time and labor associated with conventional screening techniques.

Why Creative Biolabs?

Automated Workflows

Hyperdoma™ automates key steps in the antibody production process, minimizing human error and maximizing precision.

Advanced Imaging

Utilize cutting-edge imaging systems, like Celigo, for direct visualization and analysis of live cells, ensuring high-quality antibody characterization.

Fluorometric Assays

Benefit from FMAT technology, offering high-throughput analysis with minimal interference, perfect for both cell- and bead-based assays.

Streamlined Data Analysis

Hyperdoma™ integrates seamless data analysis tools, transforming complex datasets into actionable insights.

Hyperdoma™ is a game-changer in the field of monoclonal antibody production. By harnessing the power of the electrofusion system and high-throughput screening systems, combined with a suite of innovative features, Hyperdoma™ empowers researchers to achieve unprecedented levels of efficiency, precision, and scalability in hybridoma generation. Contact us now!

Reference

Ljungars, A., et al. "A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia." NPJ precision oncology 2.1 (2018): 18. Distributed under Open Access license CC BY 4.0, without modification.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: